News

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Regulatory Roundup: New York Governor Wants Stricter Limits On Pharmaceutical Marketing; FDA Revises ICH M3(R2) Guidance.

New York Governor Wants Stricter Limits On Pharmaceutical Marketing; And More.

Regulatory Roundup

FDA issued a revised guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, which is an International Conference on Harmonization (ICH) guidance published originally in 1997. The guidance recommends international standards for nonclinical safety studies in human clinical trials and marketing authorization for pharmaceuticals. The revisions “further harmonize recommendations in a number of areas and include a new section on exploratory clinical studies,” said the document. This revised guidance discusses other nonclinical studies that should be conducted on a case-by-case basis as appropriate, including phototoxicity studies, immunotoxicity studies, juvenile-animal toxicity studies, and abuse potential studies.”

According to an Associated Press article, New York Governor David Paterson would like new, more-strict prohibitions on pharmaceutical companies when it comes to giving gifts and information to doctors. Industry disagrees with the idea, according to the article, arguing that FDA already regulates marketing practices. This isn’t the first time this topic has come up. See PharmTech's related blog posts, “Pharma Marketers May Have to Get More Creative” and “Sunshine on My (Doctor’s) Shoulder.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More